Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 199

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 199
---
,000,000 and 150,000,000 shares authorized at December 31, 2023, and 2022, respectively; 2,991,377 and 2,079,387 shares issued and outstanding as of December 31, 2023, and 2022, respectively)                                                                                              | ​ |              |         298 | ​ |              |         208 |
| Additional paid-in capital                                                                                                                                                                                                                                                                                                                 | ​ |              | 110,960,324 | ​ |              | 107,428,652 |
| Accumulated deficit                                                                                                                                                                                                                                                                                                                        | ​ |              | -98,889,581 | ​ |              | -90,726,393 |
| Total Stockholders’ Equity                                                                                                                                                                                                                                                                                                                 | ​ |              |  12,071,041 | ​ |              |  16,702,467 |
| ​                                                                                                                                                                                                                                                                                                                                          | ​ | ​            |           ​ | ​ | ​            |           ​ |
| Total Liabilities, Convertible Redeemable Preferred Stock and Stockholders’ Equity                                                                                                                                                                                                                                                         | ​ | $            |  33,795,795 | ​ | $            |  32,421,214 |

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-4

PETROS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS

| ​                                            
 ​                                            
 ​                                            
 ​                                            
 Net sales                                    
 Cost of goods sold                           
 Gross profit                                 
 Operating expenses:                          
 Selling, general and administrative          
 Warrant issuance costs                       
 Gain on settlement with Vivus                
 Research and development expense             
 Depreciation and amortization expense        
 Intangible asset impairment                  
 Total operating expenses                     
 ​                                            
 Loss from operations                         
 ​                                            
 Other income (expenses):                     
 Change in fair value of derivative liability 
 Change in fair value of warrant liability    
 Loss on issuance of Series A Preferred Stock 
 Interest income                              
 Interest expense, promissory note            
 ​                                            
 Total other income (expenses)                
 ​                                            | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​                   
 For the Years Ended 
 December 31,        
 2023                
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   
 ​                   |            ​ 
    5